$87.02
-0.82%Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Chairman of the Board, President & Chief Executive Officer
Compensation
$4,980,248
Chief Financial Officer & Executive Vice President of Finance
Compensation
$2,183,487
Executive Vice President & Group President of Medical Devices
Compensation
$2,258,516
Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products
Compensation
$1,891,684
Executive Vice President of Human Resources
Executive Vice President, General Counsel & Secretary
Compensation
$2,546,024
Executive Vice President, General Counsel & Secretary
Senior Vice President of Business & Technology Services and Chief Information Officer
Senior Vice President of Global Marketing & External Affairs
Vice President and Chief Ethics & Compliance Officer
Vice President of Investor Relations.
During the last 12 months, insiders have purchased $3.69M and sold $1.44M worth of ABT shares, resulting in $2.25M of net buying activity.
12.2K
1.13M
0
0.00
+1.1M
+$1.13M
23.8K
2.56M
4.2K
485.32K
+2.1M
+$2.07M
0
0.00
1.6K
203.04K
-203K
-$203K
0
0.00
5.5K
746.76K
-747K
-$747K
Ford Robert B
Director, Officer: Chairman And Ceo
$2.01M
Starks Daniel J
Director
$1.47M
Boudreau Philip P
Officer: Evp And Cfo
$201K
Boudreau Philip P
Officer: Evp And Cfo
$747K
Shroff Eric
Officer: Senior Vice President
$285K
Morrone Louis H.
Officer: Executive Vice President
$132K
Salvadori Daniel Gesua Sive
Officer: Evp And Group President
$102K
Moreland Mary K
Officer: Executive Vice President
$71K
Positive insider sentiment with $2.25M net buying. Buying activity substantially exceeds selling, indicating insider confidence.
Strong buy/sell ratio. Buying is at least double the selling activity, suggesting robust insider confidence.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
5 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
ABT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 13, 2026 | April 24, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 14, 2025 | April 25, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 15, 2024 | April 26, 2024 | 2024 | |
DEF 14A DEF 14A N/A | March 17, 2023 | March 17, 2023 | ||
DEF 14A DEF 14A 2022 N/A | March 18, 2022 | April 29, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 12, 2021 | April 23, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 13, 2020 | April 24, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 15, 2019 | April 26, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 16, 2018 | April 27, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 17, 2017 | April 28, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.